The invention relates to compounds of formula ##STR1## in which R.sub.1 to R.sub.9, R.sub.16 and R.sub.17 are as defined in claim 1. These compounds are pharmacologically active.
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a divisional of prior application, Ser. No. 09/593,067, filed Jun. 13, 2000, U.S. Pat. No. 6,313,120 which in turn is a divisional of prior application, Ser. No. 09/434,333, filed Nov. 4, 1999, now U.S. Pat. No. 6,100,278, which in turn is a divisional of prior application Ser. No. 09/101,214, filed Jul. 2, 1998, now U.S. Pat. No. 6,015,812, which in turn is a 35 U.S.C. .sctn.371 application of PCT International Application No. PCT/FR97/00026, filed Jan. 7, 1997, which in turn claims priority of French Application No. 9600269, filed Jan. 11, 1996.
N-Biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
N-Biphenyl(substituted methyl) aminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
Disclosed are compounds that are bradykinin B.sub.1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B.sub.1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
Disclosed are compounds of formula I and II that are bradykinin B.sub.1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B.sub.1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action. ##STR00001##
